Feature | September 26, 2014

ACC Updates Heart Attack Recommendations

September 26, 2014 — In response to new science showing that complete revascularization of all significantly blocked arteries leads to better outcomes in some heart attack patients, the American College of Cardiology (ACC) has withdrawn its Choosing Wisely recommendation that patients and caregivers examine whether this practice is truly necessary.

As part of its Choosing Wisely list of five things providers and patients should question that was released in April 2012, the ACC recommended questioning any intervention beyond unblocking just the “culprit” artery responsible for the heart attack in a hemodynamically stable patient. At the time the list was released, there were several non-randomized studies demonstrating harm to patients when treating all significantly blocked arteries. However, over the last two years, new science has emerged showing potential improvements for some patients in their overall outcomes as a result of complete revascularization.

“Science is not static but rather constantly evolving,” said ACC President Patrick T. O’Gara, M.D., FACC. “As such, one of the ACC’s primary roles is to stay abreast of this evolution and provide cardiovascular professionals and patients with the most up-to-date information on which to base decisions about the most appropriate and necessary treatment. The newest findings regarding coronary revascularization are great examples of science on the move, and we are responding accordingly.”

Results from the Complete Versus Lesion Only PRimary-PCI Trial (CvLPRIT) released earlier this month found that patients undergoing complete revascularization had better outcomes and experienced fewer major adverse cardiac events compared to those who had only their “culprit” artery revascularized. These results reinforce data from another trial, the Preventive Angioplasty in Myocardial Infarction (PRAMI) trial released in 2013, that show stenting all coronary arteries with major stenoses improves outcomes.

While some questions remain about the exact timing of the procedures; whether certain patients benefit versus others; whether fractional flow reserve (FFR) might guide decisions; and the role of patient complexity and hemodynamic stability, there is additional need for further data across larger populations. The COMPLETE trial, which is currently in the enrollment phase, will hopefully answer some of these questions over the next several years.

“Nearly 60 organizations have published lists of tests, treatments and procedures they say are overused in their specialty as part of the Choosing Wisely campaign. These lists are based on the latest science and evidence available at their time of publication,” said Daniel Wolfson, M.H.S.A., executive vice president and chief operating officer of the ABIM Foundation. “The ABIM Foundation recognizes that new research and medical guidelines are published on a regular basis and has developed a set of operating principles to ensure the accuracy of all Choosing Wisely lists is maintained. After the initial publication of a list, Choosing Wisely partners have committed to review it at least annually and also to make any needed updates based on new evidence or changes to clinical guidelines. Providing the most accurate, up-to-date information to physicians and patients is just good medicine. We appreciate ACC’s careful review and update of its Choosing Wisely list.”

O’Gara noted the ACC is working with its partners to address current clinical guideline and appropriate use criteria recommendations in light of the new research. The college will also be working with the ABIM Foundation to update its current list of recommendations, as well as develop an additional list, in the future. “The more access patients and providers have to accurate information about treatment options, the more we can ensure care that is truly necessary, free from harm and cost-effective,” O’Gara said.

For more information: www.cardiosource.org/acc

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init